Kite Seeks EU Approval for CAR T-Cell Therapy in 3 Lymphoma Subtypes – Lymphoma News Today
Lymphoma News Today |
Kite Seeks EU Approval for CAR T-Cell Therapy in 3 Lymphoma Subtypes
Lymphoma News Today Kite Pharma submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) requesting the approval of its CAR T-cell therapy, axicabtagene ciloleucel, as treatment for patients with certain lymphomas. The include relapsed … |
